Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

7.46
+0.05000.67%
Post-market: 7.29-0.1700-2.28%17:22 EDT
Volume:76.90K
Turnover:568.93K
Market Cap:65.14M
PE:0.83
High:7.55
Open:7.28
Low:7.14
Close:7.41
Loading ...

Seres Therapeutics Inc - Extends Cash Runway Into Q1 2026

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows 77% Relative Risk Reduction in Bloodstream Infections

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results From Ser-155 Phase 1B Clinical Study and Provides Corporate Updates

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows Significant Decrease in Fecal Albumin and Systemic Inflammation

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

GlobeNewswire
·
09 Jan

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Simply Wall St.
·
26 Dec 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

TIPRANKS
·
16 Dec 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

GlobeNewswire
·
16 Dec 2024

Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence

TIPRANKS
·
10 Dec 2024

Seres Therapeutics Shares up 10.2% on 'Breakthrough Therapy' Tag for Blood Infection Treatment

THOMSON REUTERS
·
09 Dec 2024

BUZZ-Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment

Reuters
·
09 Dec 2024

Seres Therapeutics granted Breakthrough Therapy designation for SER-155

TIPRANKS
·
09 Dec 2024

BRIEF-FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155

Reuters
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

THOMSON REUTERS
·
09 Dec 2024

Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025

THOMSON REUTERS
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

GlobeNewswire
·
09 Dec 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswire
·
22 Nov 2024